WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases

Microbiol Immunol. 2004;48(3):175-84. doi: 10.1111/j.1348-0421.2004.tb03503.x.


The Wilms' tumor gene WT1 is overexpressed in various types of solid tumors, including lung and breast cancer and WT1 protein is a tumor antigen for these malignancies. In phase I clinical trials of WT1 peptide-based cancer immunotherapy, two patients with advanced lung cancer were intradermally injected with 0.3 mg of an HLA-A*2402-restricted, 9-mer WT1 peptide emulsified with Montanide ISA51 adjuvant. Consecutive WT1 vaccination at 2-week intervals resulted in a reduction in tumor markers such as chorio-embryonic antigen (CEA) and sialyl Lewis (x) (SLX) and by a transient decrease in tumor size. No adverse effects except for local erythema at the injection sites of WT1 vaccine were observed. These results provided us with the first clinical evidence demonstrating that WT1 peptide-based immunotherapy should be a promising treatment for patients with lung cancer.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antigens, Neoplasm / administration & dosage*
  • Antigens, Neoplasm / therapeutic use
  • Cancer Vaccines / adverse effects
  • Cancer Vaccines / genetics*
  • Cancer Vaccines / immunology*
  • Cancer Vaccines / therapeutic use
  • Drug Delivery Systems / adverse effects
  • Drug Delivery Systems / methods
  • Female
  • HLA-A Antigens / administration & dosage
  • HLA-A Antigens / therapeutic use
  • Humans
  • Immunotherapy / methods*
  • Lung Neoplasms / etiology
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy*
  • Male
  • Middle Aged
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / immunology
  • Peptide Fragments / therapeutic use
  • Treatment Outcome
  • WT1 Proteins / administration & dosage*
  • WT1 Proteins / immunology
  • WT1 Proteins / therapeutic use


  • Antigens, Neoplasm
  • Cancer Vaccines
  • HLA-A Antigens
  • Peptide Fragments
  • WT1 Proteins